Home / Market News / $AEON

$AEON news and market catalysts

The 7 most recent market catalysts affecting $AEON, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

7 catalysts 1 high impact 6 bullish 1 bearish Biotechnology
Sep 10, 2026 Corporate Catalyst Bullish Impact 85
AEON Biopharma shares are trading higher after the company reported pilot study results showing its ABP‑450 had comparable potency loss and oxidation patterns to Botox under thermal and oxidative stress.
This headline represents a significant corporate catalyst for AEON Biopharma, as positive clinical data for a potential blockbuster drug can dramatically re-rate a company's valuat…
Sep 9, 2026 Corporate Catalyst Bullish Impact 75
AEON Biopharma Says Pilot Forced Degradation Study Showed ABP-450 And AbbVie's BOTOX Lost Potency At Comparable Rates Under Thermal Stress, Similar Methionine Oxidation Patterns; Plans Multi-Lot Comparability Study In H1 2027
The comparable degradation rates and methionine oxidation patterns under thermal stress are a positive early indicator for ABP-450's biosimilarity to BOTOX. If the multi-lot compar…
Aug 24, 2026 Corporate Catalyst Bullish Impact 55
AEON Biopharma Designates Paul Lee As Chief Regulatory Office
AEON Biopharma has appointed Paul Lee as its acting Chief Regulatory Officer. This is a positive development for the company as strong regulatory leadership is crucial for biopharm…
Aug 19, 2026 Corporate Catalyst Bullish Impact 65
AEON Biopharma Announces Final, Expanded Primary Structure Results And Preliminary Disulfide Bond Characterization Data Providing Complementary Evidence Supporting Molecular Similarity Of ABP-450 To BOTOX
AEON Biopharma released new data on its biosimilar candidate, ABP-450, showing strong molecular similarity to BOTOX. This is a crucial step in the biosimilar development process, a…
Aug 3, 2026 Corporate Catalyst Bullish Impact 55
AEON Biopharma Regains NYSE American Compliance
AEON Biopharma received notice that it is now compliant with NYSE American's continued listing standards regarding stockholders' equity. This is significant because non-compliance …
Jul 14, 2026 Corporate Catalyst Bearish Impact 75
AEON Biopharma shares are trading lower after the company announced the pricing of its upsized $13.75 million offering.
The upsized $13.75 million offering by AEON Biopharma is a significant corporate catalyst, directly impacting its share price negatively due to dilution. Investors often react poor…
Jul 14, 2026 Corporate Catalyst Bullish Impact 75
AEON Biopharma Prices Upsized $13.75M Public Offering Of 42,688,606 Shares At $0.3221/Share And And Accompanying Two-Year Milestone.
This public offering is a significant corporate catalyst for AEON Biopharma. While the capital raised provides crucial funding for their operations and research, the substantial nu…
 Join the waitlist for full signal validation →

New to reading filings? What an SEC 8-K is and why it moves prices

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.